UCB SA (OTCMKTS:UCBJF) Short Interest Down 37.2% in June

UCB SA (OTCMKTS:UCBJF) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 704,696 shares, a drop of 37.2% from the May 31st total of 1,121,617 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 831 shares, the short-interest ratio is currently 848.0 days.

UCB Stock Performance

Shares of UCBJF stock opened at $305.24 on Thursday. The company’s fifty day simple moving average is $291.85 and its two-hundred day simple moving average is $300.37. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a 1 year low of $194.76 and a 1 year high of $345.39.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.